Trading Report: The AcelRx Pharmaceuticals Inc. (ACRX) Receives Consensus Rating of “Hold” from Analysts

The AcelRx Pharmaceuticals Inc. (ACRX) Receives Consensus Rating of “Hold” from Analysts

Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) have been assigned an average rating of “Hold” from the ten research firms that are covering the firm. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.20.

Several equities research analysts have commented on the stock. Roth Capital set a $15.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. RBC Capital Markets reaffirmed a “positive” rating and issued a $6.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Stifel Nicolaus downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 0.746% during midday trading on Monday, hitting $3.325. 49,562 shares of the company traded hands. The stock’s 50-day moving average is $3.49 and its 200-day moving average is $3.32. The firm’s market capitalization is $150.66 million. AcelRx Pharmaceuticals has a 12-month low of $2.40 and a 12-month high of $5.88.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. AcelRx Pharmaceuticals had a negative net margin of 111.47% and a negative return on equity of 94.98%. The firm earned $4.53 million during the quarter, compared to the consensus estimate of $2.17 million. Analysts anticipate that AcelRx Pharmaceuticals will post ($0.93) EPS for the current fiscal year.

In related news, major shareholder Perceptive Advisors Llc sold 216,500 shares of the firm’s stock in a transaction on Thursday, September 29th. The shares were sold at an average price of $3.92, for a total value of $848,680.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of AcelRx Pharmaceuticals by 2,427.4% in the second quarter. State Street Corp now owns 424,598 shares of the specialty pharmaceutical company’s stock worth $1,142,000 after buying an additional 407,798 shares in the last quarter. Advisor Group Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $355,000. Rhumbline Advisers purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $103,000. Teachers Advisors Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $157,000. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of AcelRx Pharmaceuticals by 73.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 962,026 shares of the specialty pharmaceutical company’s stock worth $2,588,000 after buying an additional 406,974 shares in the last quarter. Hedge funds and other institutional investors own 35.85% of the company’s stock.

Related posts

Leave a Comment